Pacira BioSciences’ ROIC of 1.74% Falls Short of 6.19% WACC; PTC ROIC at 37.4%
Pacira BioSciences’ ROIC stands at 1.74%, below its 6.19% WACC, indicating capital utilization inefficiencies. By contrast, PTC Therapeutics posts a 37.39% ROIC against a 7.70% WACC, highlighting its superior capital efficiency among pharmaceutical peers.
1. Pacira’s Capital Efficiency Shortfall
Pacira BioSciences reports a 1.74% ROIC versus a 6.19% WACC, failing to generate returns above its cost of capital. This gap suggests inefficiencies in deployment of funds and could weigh on profitability and shareholder value if unaddressed.
2. PTC Therapeutics’ Superior Performance
PTC Therapeutics achieves a 37.39% ROIC against a 7.70% WACC, yielding a ROIC/WACC ratio of 4.86. This demonstrates strong capital allocation and positions PTC as an efficiency leader within the non-opioid pain management and biotech sector.
3. Peer Landscape and Implications
Ironwood Pharmaceuticals shows solid metrics with a 21.34% ROIC and 5.68% WACC, while Ultragenyx and Enanta record negative ROICs, underscoring divergent capital strategies. These variations highlight the competitive pressures and potential strategic shifts needed across the group.